Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + letrozole + palbociclib
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of three drugs used for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Palbociclib is a CDK4/6 inhibitor that prevents cells from transitioning from G1 phase to S phase of the cell cycle. Letrozole is an aromatase inhibitor that reduces estrogen production. Everolimus is an mTOR inhibitor that targets resistance mechanisms to prolong response duration for endocrine therapy. This specific three-drug combination aims to provide multiple mechanisms to overcome resistance in advanced breast cancer.
02
Targets
CYP19A1 (Aromatase)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on everolimus + letrozole + palbociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + letrozole + palbociclib.